Morning Movers Gapping up $星巴克(SBUX.US)$stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December. $諾和諾德(NVO.US)$stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the$SPDR標普生物科技ETF(XBI.US)$has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the$標普500指數(.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
$BridgeBio Pharma(BBIO.US)$BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023 2 MINUTES AGO, 7:30 AM EST VIA GLOBENEWSWIRE
$BridgeBio Pharma (BBIO.US)$ it need to filled the gap, so it will go down soon to $25 - $18 soon. plus it is just a good new about the drug not FDA approval. while you are still having profit, take it!
BridgeBio Pharma股票討論區
📊⚡️📊
Gapping up
$星巴克(SBUX.US)$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$諾和諾德(NVO.US)$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
@ $Carvana(CVNA.US)$ $BridgeBio Pharma(BBIO.US)$
Up Up Up to the moon~
暫無評論